Senti Biosciences Inc (SNTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Senti Biosciences Inc (SNTI) has a cash flow conversion efficiency ratio of -1.163x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.45 Million) by net assets ($8.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SNTI defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Senti Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Senti Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Senti Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Senti Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shradha Infraprojects Limited
NSE:SHRADHA
|
-0.127x |
|
SeaTwirl AB
ST:STW
|
0.567x |
|
Crypto Blockchain Industries SA
PA:ALCBI
|
-0.428x |
|
INTERSHOP Communications Aktiengesellschaft
XETRA:ISHA
|
0.244x |
|
EMMERSON PLC O.N.
F:4UM
|
N/A |
|
Shenzhen Shenbao Industrial Co Ltd
SHE:200019
|
0.124x |
|
Tontek Design Technology Ltd
TWO:5487
|
0.022x |
|
Filter Vision Public Company Limited
BK:FVC
|
-0.091x |
Annual Cash Flow Conversion Efficiency for Senti Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Senti Biosciences Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Senti Biosciences Inc (SNTI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $25.65 Million | $-41.40 Million | -1.614x | -106.12% |
| 2023-12-31 | $66.91 Million | $-52.40 Million | -0.783x | -185.57% |
| 2022-12-31 | $127.26 Million | $-34.90 Million | -0.274x | +52.20% |
| 2021-12-31 | $60.38 Million | $-34.63 Million | -0.574x | -239.33% |
| 2020-12-31 | $-58.71 Million | $-24.17 Million | 0.412x | +140.25% |
| 2019-12-31 | $17.96 Million | $-18.38 Million | -1.023x | -- |
About Senti Biosciences Inc
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications w… Read more